Since data was collected in 2016, it must be noted that drug therapy has changed significantly in the meantime due to the introduction of angiotensin receptor neprilysin inhibitors (ARNI) and Sodium-glucose co-transporter-2 (SGLT-2) inhibitors followed by the adaptation of the European heart failure guidelines. This evidence concerns the gene SLC5A2 and heart failure.